Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · SCHEDULE 13G

CDT Equity Inc.

SEC Filing

Filed Sep 9, 2026Accepted Sep 9, 2026, 6:09 PM EDTCIK 1896212Accession 0001753926-26-001737
Share

Company context

CDT Equity is a data-driven biotech development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The Company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel therapeutic treatments.

Current securities

Historical securities (3)

Recent company filings

  1. 424B3 filingSep 18, 2026
  2. Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity SecuritiesSep 18, 2026
  3. 424B3 filingSep 18, 2026
  4. EFFECT filingSep 17, 2026
  5. S-1 filingSep 8, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗